KD019 Versus Erlotinib in Subjects With Stage IIIB/IV Non Small Cell Lung Cancer With Progression After First- or Second-Line Chemotherapy
Conditions
Non Small Cell Lung Cancer
What is the purpose of this trial?
This is a research study designed to look at the effects of an investigational chemotherapy drug, KD019, on non small cell lung cancer in comparison to a standard chemotherapy drug, Erlotinib ( Tarceva®).Participation Guidelines
- Age:
- 18 Years and older
- Gender:
- Both
Click here for detailed information about who can participate in this trial.
- Sponsor:
- Kadmon Corporation, LLC
- Dates:
- November 2012
- Last Updated:
- Study HIC#:
- 1204010034
Clinicaltrials.gov ID: Yale4409252
